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Abstract
Background: The pre-nodal afferent lymph is the fluid which directly derives from the extracellular milieu from every
parenchymal organ and, as it continues to circulate between the cells, it collects products deriving from the organ
metabolism/catabolism. A comprehensive qualitative and quantitative investigation of the self-antigenic repertoire
transported by the human lymph is still missing.
Methodology/Principal Findings: A major difference between lymph and plasma could be visualized by FPLC and 2D gel in
the amount of low molecular weight products corresponding to peptide fragments. Naturally processed peptides in normal
pre-nodal human lymph were then fractionated by HPLC and characterized by multidimensional mass spectrometry.
Analysis of more then 300 sequences identified self-peptides derived from both intracellular and extracellular proteins
revealing the variety of catabolic products transported by human lymph. Quantitative analysis established that at least
some of these peptides are present in the circulating lymph in nanomolar concentration.
Conclusions/Significance: The peptidome, generated by physiological tissue catabolism and transported by the pre-nodal
lymph, is in addition to the self-peptidome generated in endosomal compartment. Unlike self antigen processed by local or
nodal APC, which mostly produce epitopes constrained by the endosomal processing activity, self antigens present in the
lymph could derived from a wider variety of processing pathways; including caspases, involved in cellular apoptosis, and
ADAM and other metalloproteinases involved in surface receptor editing, cytokines processing and matrix remodeling.
Altogether, expanding the tissue-specific self-repertoire available for the maintenance of immunological tolerance.
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Introduction
Four mechanisms are likely to guarantee processing and
presentation of a wide variety of tissue-specific self antigens: (i)
self proteins are phagocytosed and processed in peripheral tissue
by local antigen presenting cells and displayed to T cells patrolling
peripheral organs [1]; (ii) products of ‘‘self’’ are carried through the
lymphatic system by circulating dendritic cells (DC) [2–6]; (iii)
lymph nodal cells expressing AIRE encode tissue-specific proteins,
similarly to thymic epithelial cells [7,8]; (iv) self antigens are
transported from the parenchymal tissue to the draining lymph
nodes, through the lymphatic system [9,10]. The first three
mechanisms rely on antigen processing and presentation by
parenchymal and nodal APC, which mostly produce an MHC
class II peptidome restricted by endosomal proteases, among
which cathepsins have been characterized in greatest details [11].
The last mechanism is the least characterized among the four,
mostly due to the great difficulty to obtain primary lymph
material. As such, a comprehensive qualitative and quantitative
investigation of the self-antigenic repertoire transported by the
lymph is still missing.
Lymphatic fluid (lymph) is derived from the tissue fluid
compartment and constitutes up to 20% of the body weight
[12]. Four different types of lymph have been classified: 1)
interstitial lymph that is enclosed in the intercellular spaces
throughout the body; 2) circulating lymph that circulates through
the lymphatic vessels towards the veins; 3) chyle, the circulating
lymph collected from the intestinal epithelia during digestion; and
4) serous lymph, the liquids normally contained in the pleural,
peritoneal and pericardial cavities, in the cerebral ventricles, and
the cerebro-spinal fluid. The tissue lymph is the fluid which
directly derives from the extracellular milieu from every
parenchymal organ, and as it continues to circulate between the
cells, it collects products deriving from the organ metabolism/
catabolism [13]. In order to be transported to the lymph nodes,
the lymph is then collected into lymphatic capillaries, which form
a mesh-like network of blind-end tubes distributed throughout the
tissue spaces. The capillaries flow into progressively larger
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lymphatic vessels that transport the pre-nodal lymph to the 400–
500 lymph nodes disseminated throughout the human body [14].
The lymph enters through the cortical area of the node and by
traveling through the conduit system in the inter follicular T cell
areas conveys a representative sampling of the interstitial fluid to
the nodal antigen presenting cells before entering the central vein
located in the nodal sinus [14–17].
In general it has always been assumed that the lymph would
contain a qualitatively similar protein composition as the
plasma. A previously published partial comparative proteomic
analysis between bovine lymph and plasma indicated indeed an
almost overlapping proteomic between the two samples with
only few proteins being differentially expressed [12]. As in
plasma, the most abundant proteins where identified as
albumin, immunoglobulins, transferrin, fibrinogen and apolipo-
proteins [12]. However, differently from the plasma, the lymph
directly collects from the extracellular milieu of each parenchy-
mal organ; thus it could potentially be a much richer source of
peripherally derived tissue specific antigens. Indeed, experi-
ments of cellular and extracellular ‘‘in vivo’’ radioactive labeling
as well as cellular tracking have indicated that products of
cellular apoptosis and extracellular matrix turnover are found in
the lymph [18,19].
The primary hypothesis that initiated this investigation was that
the lymph could potentially carry a wider antigenic repertoire than
the plasma and be a richer source of tissue specific antigens.
Additionally, we also hypothesized that, differently from plasma;
the lymph could carry a partially processed proteome/peptidome
since it directly collects from the extracellular milieu where
products of tissue catabolism, tissue remodeling, cellular apoptosis,
and extracellular matrix processing are collected before being
transported to the draining lymph nodes.
In this work we present an in depth MS/MS and quantitative
analysis of the pre-nodal human lymph, which does indeed
indicate an expanded self-antigen repertoire carried by the human
lymph as compared to plasma from the same subjects. The
proteome/peptidome, generated by physiological tissue catabo-
lism, and transported by the lymph is additional to the self-
peptidome generated in endosomal compartment; altogether
expanding the tissue-specific self-repertoire available for the
maintenance of immunological tolerance.
Results
Self-Peptidomic Analysis of the Human Lymph
A previously published proteomic analysis of the bovine lymph
identified several major proteins common to both lymph and
plasma (albumin, fibrinogen, IgG, transferrin, lactoferrin and
apolipoproteins) and altogether indicated a qualitatively similar
protein profile between the two samples [12–13]. Complementary
to this analysis we performed a comparative analysis between
human lymph and subject-matched plasma pooled from 18
individuals (Figure 1a). Since the presence of very abundant
proteins could interfere with the analysis, samples were depleted of
albumin and IgG prior to 2D gel analysis. An almost overlapping
proteomic profile could be observed between the two samples;
however, an observed major difference between lymph and plasma
could be visualized in the 2D gel in the amount of low MW
products (Figure 1b). Similarly, comparative reverse phase HPLC
analysis of lymph and plasma samples indicated substantial
overlap between the two (Figure 1c and 1d) except for a broad
peak eluting at around 30–40 minutes (Figure 1c, 1d boxed area).
This peak had a 100-fold greater intensity in the lymph as
compared to the plasma (Figure 1e).
To further analyze the low molecular weight species present in
the human lymph, samples of pooled lymph (from 18 subjects)
were treated in the presence or absence of 0.1% TFA to release
any additional peptide possibly bound to serum and plasma
proteins (Figure 2a, 2b), before ,5000 MW cutoff ultrafiltration
and multidimensional mass spectrometry scan (200–2000 m/z)
analysis. A significant pool of peptides was present in both
untreated (Figure 2a) and TFA-treated (Figure 2b) samples. To
facilitate MS/MS identification of each molecular species, eluted
peptides were first either fractionated by FPLC on a Superdex
peptide gel-filtration column (Figure 2c) or by HPLC, on a C18
reverse-phase, column (Figure 2e). Each fraction was then
analyzed by tandem MS/MS using Nanospray LC-MS/MS on
a LTQ linear ion trap mass spectrometer (Figure 2d and 2f). The
tandem MS/MS identified more than 300 peptides using
MASCOT and SeqQuest algorithms and non-redundant NCBI
and SwissProt databases (see Methods for details).
The identified self-peptides derived from both intracellular and
extracellular proteins revealing the variety of catabolic products
transported by human lymph (Figure 3 and Figure S1). A large
number of the sequenced peptides derive from the immunoglob-
ulin family (6.8%), complement (2.6%) and fibrinogen (5%).
Several peptides derived from processed plasma membrane-
associated or soluble receptors (8.2%) as well as cadherins and
cell adhesion molecules (2.1%) (Figure 3a and Figure S1). A major
category of sequenced peptides derived from processing of
extracellular matrix proteins (20.3%). Many others (26%) were
categorized as miscellaneous and a relatively large pool (11.1%)
was represented by peptides of unknown origin (Figure 3 and
Figure S1). A breakdown analysis of the miscellaneous peptide
pool indicated the presence of peptides derived from processing of
proteins from the cytoskeleton, exo/endocytosis and several
regulatory proteins together with kinines and derived regulatory
peptides (Figure 3b). In addition, the statistical analysis of the
extracellular matrix peptide pool revealed collagens as a dominant
population (75.6%), followed by laminins (9.3%) (Figure 3c).
Altogether the analysis indicates that the majority of sequenced
peptides derive from catabolic processing of extracellular or
plasma membrane bound proteins (Figure 3 and Figure S1).
Many peptides carried by the human lymph are derived
from the degradation of extracellular matrix proteins
Since a large number of peptides retrieved from human lymph
derived from extracellular matrix components, we further focused
our study on the detailed analysis of the self-peptidome of the
human extracellular matrix. More than 70 peptides were
sequenced and almost all classes of collagens were found. Peptides
derived from laminin alpha1, alpha4, alpha5, gamma 1–3 were
also found in the proportion described in Figure 3c. Less
represented were peptides derived from fibrosin, cartilage protein,
adlican, mucins and fibronectin catabolism (Figure 4).
The large number of peptides derived from extracellular matrix
turnover prompted us to address the issue of whether these
peptides were present in a quantifiable amount. To determine this
total lymph, previously depleted of immunoglobulin and albumin,
was run on a 2D 16% SDS-PAGE gel to resolve the low molecular
weight peptide species. Silver staining analysis identified several
spots around and below 3000 kDa (Figure 5a). Single spots were
extracted from the gel and analyzed by LTQ-MS/MS coupled
with database search using MASCOT algorithm (Figure 5b). A
significant amount of the peptides (16% of the total number of
sequenced peptides) were derived from extracellular matrix
proteins, with the highest population represented by the collagens
(Figure 5b and data not shown).
Self Antigens in Human Lymph
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To quantify the amount of peptides present in a single 2D spot we
selected spot number 6 for gel extraction and LTQ-MS/MS analysis.
Three peptides were sequenced from spot number 6 (Figure 5c).
Visualization of silver stained proteins is dependent on both total
amount and physical characteristics (amino acid primary sequence
and overall peptide length) of the protein; however, in general silver
staining can visualize an amount of protein in the low nanogram
range. For short peptides, a much greater amount is needed to be
visible in silver staining. The relative absorbance of the three
combined gel-extracted peptides was determined at 230 nm
(extinction coefficient 300 M-1 cm-1 per peptide bond), assuming
an average length of 19 residues (18 peptide bonds), an extinction
coefficient of 5,400 was determined. Altogether the three gel eluted
peptides were quantified to be around 0.22 mm. A more quantitative
measurement was performed on the material eluted from spot
number 6 by quantitative amino acid analysis which indicated a total
peptides concentration of 180 ng (data not shown). Altogether, the
2D quantitative analysis of peptides derived from collagens and other
extracellular matrix antigens established that at least some of these
peptides are present in the circulating lymph in nanomolar
concentration. Peptide therapies for tolerance induction have been
previously shown to be effective even at sub-nanomolar peptide
concentration.
HLA-DR-1 and HLA-DR-4 MHC class II binding and
immune recognition of extracellular Matrix Peptides
Next we determined whether any of the extracellular matrix
fragments sequenced from the human lymph were able to bind to
MHC II molecules. We tested HLA-DR1 and HLA-DR4
molecules since many autoimmune diseases with self reactivity to
extracellular matrix proteins are HLA-DR1 or HLA-DR4
associated [22–23]. A positive control peptide, previously reported
to represent a bona fide extracellular matrix autoantigen presented
by HLA-DR1 and HLA-DR4 [21], was included in the analysis
(AGFKGEQGPKGEP from Collagen I a1, IC50 1.5 uM).
We identified potential HLA-DR1 or HLA-DR4 binding
regions within the extracellular matrix fragment sequences from
human lymph, using an efficient prediction algorithm [21]. For
each potential nonameric binding frame, we synthesized a 12–15
residue peptide containing the region of interest in its natural
context, and determined the binding affinity using a competition
fluorescence polarization assay (Figure 6a). Several peptides
binding with affinity comparable to the test autoantigens were
identified, including peptides from collagen II a1, collagen XII a1,
cartilage-derived morphogenic protein, and adlican for HLA-DR1
and collagen VI a2, laminin a1, laminin a5, and fibronectin for
HLA-DR4 (Figure 6b).
Figure 1. Comparative peptidomic profile of human lymph and plasma samples. a) Comparative 2D-gel analysis of human lymph and
plasma proteins (2CyDye). b) Fluorescence (2CyDye) comparative 2D-gel analysis of human lymph and plasma low molecular weight products (1–
10 kDa). One out of 6 silver staining gels is shown c) Overlays of reverse phase HPLC profile of lymph and plasma low MW filtrates (,5000 Da).
Samples from 18 subjects were pooled. d) is a 10 times magnification of c. Boxed areas indicate where major differences between the two samples
are observed. One out of four reverse phase HPLC analysis is shown. e) Bar graph representing the integration number calculated from the curves in
the boxed area for both the lymph and the plasma pooled samples.
doi:10.1371/journal.pone.0009863.g001
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Finally we asked whether any of the tight-binding peptides,
which also were conserved between mouse and human, could be
recognized by peripheral T cells. HLA-DR1 or HLA-DR4
transgenic mice were immunized with 100 mg of several of the
extracellular matrix peptides in complete Freund’s adjuvant in the
flanks and nape of the neck. Draining lymph nodes were collected
14 days later and reactive T cells analyzed by proliferation assay
with thymidine incorporation. A significant proliferation index was
observed in response to some of the immunizing antigens
(Collagen XII, Adlican and Laminin a5). The result indicates
that autoreactive T cells specific to these antigens are present in
the peripheral T cell repertoire (Figure 6c).
Discussion
We report here a comparative analysis of the overall self
antigenic repertoire present in the human lymph as compared to
plasma from matching donors. We confirmed as previously
established that the overall proteomics between lymph and plasma
is very similar with only few proteins uniquely expressed in the
lymph but not in the plasma [12,13]. Unexpectedly, however, we
also find that a major difference between lymph and plasma is in
the peptidome profile. Whereas very few peptides are found in the
plasma, a much greater amount of protein fragments and short
peptides are present in the lymph.
Sequence analysis of more then 300 peptides indicates that
processed fragments derived from both intracellular and extracel-
lular proteins. When the peptidome profile described here was
compared to previously published MHC class II eluted peptidome,
it appeared that the lymph peptide repertoire is partially skewed
towards peptides derived from extracellular matrix proteins,
cadherins and cleavable or soluble receptors (43%) [24,25].
Some of the peptides we identified in the human lymph were
derived from intracellular proteins. These are likely byproducts
from apoptotic cells. In physiological cell catabolism, older
differentiated cells are mostly removed by apoptosis and replaced
by the progeny of tissue adult stem cells [26–30]. Apoptotic cells
are mostly phagocytosed ‘‘in situ’’ by tissue macrophages and
dendritic cells; however, some apoptotic cells have also been found
in the circulating lymph [19]. Thus, partially processed proteins
Figure 2. MS peptidomic profile of the human lymph. a and b) Mass spectroscopy scan (200–2000 m/z) of low MW (5000 Da) filtrate from
lymph samples obtained before or after elution in 0.1% TFA. c) Elution profile of the low MW filtrate (,5000 Da) collected from the lymph pooled
samples run through a superdex peptide 10/300 GL column d) MS scan of eluted fractions 11–12. e) Representative elution profile of the low MW
filtrate (,5000 Da) collected from the lymph pooled samples run through a C18 column f) Representative full MS scan of eluted fraction 34.
doi:10.1371/journal.pone.0009863.g002
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and peptides from intracellular origins found in the human lymph
are likely released by the dying cells [19].
On the other hand, lymph-carried peptides derived from the
catabolism of the extracellular matrix likely reflect the constant
remodeling of the extracellular connective tissue [18,31]. The
extracellular matrix components constitute a structure that helps
to maintain tissue integrity, regulates cell growth, division and
migration, and provides a reservoir of cytokines, chemokines and
growth factors [32–35]. By its very nature, the extra-cellular
matrix is constantly undergoing changes and it has been previously
estimated that collagen in the skin and in parenchymal organs has
a very rapid turnover (10–30% day). The turnover is accelerated
in response to various cellular stimuli which range from dynamic
homeostasis to full-blown tissue remodeling, as occurs during
inflammation, wound healing, and cancer [35].
Data from the sequencing analysis prompted us to ask whether
the self antigens peptide fragments, generated by physiological
tissue catabolism, found in the human lymph would play a role
towards the maintenance of peripheral tolerance. From an
immunological standpoint for the lymph carried peptides to be
tolerogenic their amount should be in a quantitative relevant
amount. To this end we compared the amount of peptides found
in our analysis with the amount previously determined to be
effective is several peptide-based therapeutic vaccines aimed at
recovery of immunological tolerance [36–38]. Peptide therapy
have been shown to reduce immune responses to allergens and
down-regulate cytokines and T cell proliferative responses in
different diseases among which asthma, rheumatoid arthritis, type
1 diabetes and cat and bee allergy [39–43]. Mice experimental
work indicate dose ranges between few micrograms to milligrams,
human clinical trials report effectiveness of few micrograms of
subcutaneously injected peptides in the treatment of asthmatic
individuals [36]. Peptide concentration it is recognized to be
important in inducing low versus high tolerance. It is generally
accepted that high peptides regiments induce tolerance by
depleting auto-reactive antigen specific T cells as well as inducing
regulatory T cells; on the other hand low peptides regiments only
appear to induce regulatory T cells [36]. Low dose tolerance is
induced upon injection of sub-immunogenic doses of soluble
antigens and therapeutical efficacy has been demonstrated even
with sub-nanomolar doses of antigens [37]. In our analysis we
determined that several peptides could be visualized on a 2D gel
and estimated to be in high-nanomolar concentration. Important-
ly, peptides directly found in the lymphatic fluid are readily and
constantly available to nodal antigen presenting cells. In
experimental immunization and in peptide-therapy clinical trials
one dose of peptide is administered weekly or even monthly either
subcutaneously or intradermally and no data are available on
determining the actual peptide concentration reaching the blood
and the lymph [36].
With regard to the APC population targeted by the lymph-
carried peptides, it has been previously established that subcuta-
neously injected antigens are transported to the lymph node sub-
cortical macrophages and by the conduit system to the
interfollicular DC [10]. It is likely that lymph-transported peptides
are also delivered to the immature DC associated with the conduit
system. Once in the lymph node, peptides could load directly at
the cell surface of immature DC as previously reported, either on
empty MHC class II molecules or by exchanging with previously
loaded peptides at the plasma membrane or in early recycling
compartments [44,45]. On the other hand, protein fragments and
longer peptides are more likely to be internalized for MHC class II
Figure 3. Schematic representation of the MS/MS peptidomic profile of the human lymph. a, b and c) Pie chart representation of self-
peptides (,5000 Da) sequenced from the human lymph. Data are compiled from 4 independent MS/MS analysis.
doi:10.1371/journal.pone.0009863.g003
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loading in endosomal multivesicular bodies [46] or following the
cross presentation pathway for MHC class I loading [47].
In conclusion even though it has often been hypothesized that
the lymph would collect material from parenchymal cell and
extracellular matrix catabolism, this is the first analysis that
actually proves that an immunologically relevant amount of
proteins, partially processed proteins and peptides are carried by
the human lymph. The extracellular peptidome describe herein
likely reflect the protein composition of the tissues (skin, adipose
tissue, connective and muscle) represented at the site of lymph
collection. In the future it would be of interest to compare pre-
nodal lymph collected from capillaries draining different tissues to
determine a tissue specific proteome/peptidome. Unlike self
antigen processed by local or nodal APC, which mostly produce
epitopes constrained by the endosomal processing activity, self
antigens present in the lymph could derived from a wider variety
of processing pathways; including caspases, involved in cellular
apoptosis, and ADAM and other metalloproteinases involved in
surface receptor editing, cytokines processing and matrix remod-
eling. Altogether, broadening the sample of peptides available to
endosomal and plasma membrane MHC class II loading.
Materials and Methods
Collection of pre-nodal lymph and plasma
Subjects. Eighteen healthy males aged 22 to 36 years were
studied. All had been given a full medical examination, and
screened by EKG and laboratory examination to exclude
cardiovascular, liver, renal, endocrine and hematologic disease,
and recreational drug abuse. None was taking a special diet or
medication. The study had been approved by the Royal London
School of Medicine Committee for Clinical Investigation, and all
subjects gave informed written consent. The Albert Einstein
College of Medicine, Committee for Clinical Investigation,
approved the analysis on human lymph and plasma. Alcohol
was avoided for 48 hours before and during the study.
Clinical Procedures. Prenodal peripheral lymph was
collected as previously described [20]. Subjects were admitted to
a metabolic ward 24 or 48 hours before the collection, and placed
on an isocaloric diet. Lymph vessel cannulations were per formed
between 8:00 and 11:00 a.m in a surgical theater under full sterile
conditions. The subjects had been fasted overnight, but allowed
unlimited access to fluids. The lower part of one leg was shaved to
about 20 cm above the ankle, and the skin sterilized with 0.05%
chlorhexidene. An area of skin (4 cm2) 6–10 cm above the ankle
over the anteromedial aspect was anesthetized with subcutaneous
2% lignocaine in 1:100,000 epinephrine. A horizontal 15–20 mm
incision was made in this area. Under an operating microscope,
the subcutaneous lymph vessels were dissected, and one was
selected for cannulation. A second small incision (3 mm) was made
10 mm above the first, through which a cannula (IntramedicH
polyethylene tubing PE60; Becton Dickinson & Company, Sparks,
MD; cat. no. 427416; i.d. 0.76 mm, o.d. 1.22 mm) was passed.
The cannula was inserted into the vessel for 5–10 mm (towards the
foot), and secured with a silk ligature (Mersilk, 5/0). The other
(untapered) end of the cannula was passed into a 2-mL screw-
topped polypropylene cryovial (Nunc A/S, Roskilde, Denmark). A
blood sample from each subject was also drawn. Blood and lymph
Figure 4. Amino acid sequence of self-peptides derived from processing of extracellular matrix proteins found in the human
lymph. MS/MS sequencing analysis of peptides found in the human lymph, which derive from processing of extracellular matrix proteins.
doi:10.1371/journal.pone.0009863.g004
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samples were centrifuged at 1,500 g for 15 min at 4uC, and the
supernatants transferred to polypropylene microcentrifuge tubes
[20]. Samples were supplemented with a cocktail of proteases
inhibitors (Roche).
2D DIGE Protein Expression Profiling of human lymph
and plasma
Equal amounts of protein from whole lymph and plasma
(pooled from 18 patients) (between 2 and 6 mg/sample) were
depleted of immunoglobulins and albumin using the Aurum
Serum protein kit (Biorad). Fifty ug of each sample was subjected
to fluorescence labeling using 2 dyes (Cy3 for plasma and Cy5 for
lymph) and to 2D-DIGE preparative electrophoresis (Applied
BIOMICS Inc. facilities, Hayward, CA). After electrophoresis, the
gel was scanned using a Typhoon image scanner and the images
were analyzed using the DeCyder software. Protein spots of
interest were automatically picked from the 2D gel with the Ettan
Spot Picker, subject to tryptic digestion and MS/MS analysis.
Fractionation of lymph and plasma for mass
spectroscopy analysis
An equal amount of proteins from both plasma and lymph
(10 mg) were filtrated through Centriplus (Amicon) centrifugal
filter devices (5,000 Da cut-off). A cocktail of protease inhibitors
(Roche) was added to each sample to avoid proteolysis. The filtrate
was quantified by UV measurements at 230 nm (for determination
of peptide concentration). In an independent experiment, samples
(10 mg) were treated with trifluoroacetic acid (TFA) (at 0.1% final
concentration in the sample) to extract the peptides adsorbed on
different proteins, chaperones and albumin. Peptide sample
filtrates were then lyophilized, resuspended in 0.1% TFA and
subjected to desalting using ZipTip (C18) reversed-phase system
(Millipore, Billerica, MA) or PepClean C-18 spin columns (Pierce).
High pressure liquid chromatography (HPLC) and gel-
filtration chromatography of plasma and lymph filtrates
Plasma and lymph (5,000 kDa filtrates) were separated using a
reversed-phase system (buffer A: 0.1% TFA and buffer B: 0.1%
TFA in acetonitrile) on a C18 column on a Hewlett Packard
HPLC system (1100 series). Alternatively, plasma and lymph
filtrates were run through a Superdex peptide 10/300 gel filtration
column (Tricorn) in 30% acetonitrile in 0.1% TFA as solvent.
Each fraction was lyophilized before mass spectroscopy analysis.
LTQ-tandem MS/MS sequencing of peptides from lymph
filtrates
LTQ-MS/MS sequencing of peptides present in the lymph
(5,000 kDa filtrates) or from HPLC or gel-filtration fractions was
performed using Nanospray LC-MS/MS on a LTQ linear ion
trap mass spectrometer (LTQ, Thermo, San Jose, CA) interfaced
Figure 5. Quantification of 2D gel eluted peptide. a) Silver staining of an SDS-PAGE run with 20 microgram of immunoglobulin and albumin
depleted lymph. b) Sequence of some of the peptides retrieved from each of the analyzed spot. c) MS/MS fragmentation profile and respective
sequence of the three peptides eluted from spot number 6. Green dotted lines identified assigned fragmentation picks. Total peptide concentration
eluted from spot number 6 calculated at 230 OD was 0.22 mM.
doi:10.1371/journal.pone.0009863.g005
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with a TriVersa NanoMate nanoelectrospray ion source (Advion
BioSciences, Ithaca, NY). MS/MS was performed using an
isolation width of 2 m/z, normalized collision energy of 35%
and a minimum signal intensity of 1000 counts. The sequences of
each peptide were determined using the LTQ software analysis
MS (mass spectroscopy) database searching with MASCOT
(Mowse score above the predicted identity score) and SEQUEST
(Delta Cn above 0.15, Sp200 percentage ions above 80 and Xscorr
above 2) algorithms). The MS/MS scans were screened against
NCBInr database as a first choice and then validated against
SWISSPROT database.
Fluorescence polarization Peptide binding assays
To evaluate the binding affinities of peptides to HLA-DR1
(HLA-DRA*0101,-DRB1*0101) and HLA-DR4 (HLA-
DRA*0101,-DRB1*0401) molecules a competition assay was
performed in a 96-well setting. The assay is based on the
differential fluorescence polarization of MHC-bound and free test
peptide acetyl-PRYVKQNTLRLAT, derived from influenza
hemagglutinin 306–318 and labeled at the internal lysine residue
using the amine-reactive reagent Alexa488-tetrafluorophenyl ester
(Invitrogen). Serial dilutions of unlabeled peptide competitors
(,10 uM to ,30 nM) were incubated with Alexa488-HA peptide
(25 nM) and with either HLA-DR1 (100 nM) or a mixture of
HLA-DR4 and HLA-DM (100 nM each). HLA proteins were
prepared as soluble extracellular domains expressed in insect cells
as described [21]. Unlabeled HA peptide was used as a control
competitor. MHC-peptide mixtures was incubated for 3 days at
37uC in 100 mM sodium citrate (pH 5)/50 mM sodium chloride
buffer (pH 5.5), containing 0.25% octylglucoside, 185 ug/ml
iodoacetamide (IAA), 25 nM EDTA, 0.1% NaN3 and freshly
added 0.5 ug/ml PMSF. For HLA-DM incubations 1 mM DTT
was added instead of IAA. Polarization measurements were
performed in a POLARstar OPTIMA plate reader (BMG
Labtech), using the fluorescence polarization detection mode
and 485 nm excitation and 520 nm emission filters. Fluorescence
polarization values for free and MHC-bound Alexa-HA peptide
were 70 and 350 mP, respectively. IC50 values were evaluated
using a competitive binding equation in GraphPadPrism, and are
reported as mean and standard error for single fit to triplicate
experimental values. IC50 value for the control unlabelled HA
peptides was 25 nM.
2D-electrophoresis of proteins from whole human lymph
For 2-D analysis of whole lymph, the lymph sample (10 mg
protein) was pre-cleaned using the 2-D cleaning kit from Biorad.
Aliquots of pre-cleaned 50 ug protein sample were further
resuspended in 2D-EF loading buffer containing 7 M urea, 2 M
thiourea, CHAPS (4%), NDSB 256 (5%), protease cocktail
inhibitors (Roche), 10 mM Tris, pH 8.0 and IPG buffer (0.5%)
(pH 3–10 NL from GE Healthcare). Samples were loaded on an
Immobiline DryStrip, pH 3–12, NL, 13 cm, Biorad and run for
isoelectric focusing for the first dimension. Strips were rehydrated
for a total of 14,934 Vhours. The second dimension was
conducted on a 4–10% SDS-PAGE protein gel or on a 10–20%
Tris/Tricine/SDS peptide gel. The gels were stained using
standard procedures with silver stain (SilverSNAP stain kit,
Pierce). For tandem MS/MS sequencing of peptides with
MW,5000 Da, the peptides were extracted from the gel in a
solution containing 50% acetonitrile and 0.1% TFA, at 37uC,
overnight. The extracted peptides were further analyzed in
tandem MS/MS mode using LTQ, ESI (+) mode as described
above.
Peptide Immunization, T cell Proliferation
HLA-DR1 and HLA-DR4 mice were immunized in the flanks
and nape of the neck with 100 micrograms of peptide emulsion in
Freund’s adjuvant. Two weeks later popliteal and axillary lymph
nodes were harvested and tested in proliferation assay. Briefly
66105 cells were seeded in a 96 well plate with or without titrated
Figure 6. HLA-DR1 and HLA-DR4 binding affinity and T cell
proliferative response to some of the lymph sequenced
peptides. a) IC50, as determined by competitive fluorescence
polarization assay, for short peptides derived from fragments identified
in lymph. Peptides were selected based on predicted binding of
nonameric binding frames (capital letters) to HLA-DR1 or HLA-DR4.
Peptides were synthesized with N-terminal acetyl and C-terminal amide
groups unless the peptide termini were coincident with an end of the
sequenced fragment, in which case the native terminus was used b)
Position of the assayed peptides in the sequenced fragments indicated
by bars above the sequence. c) Proliferative responses (calculated by
thymidine incorporation assay) in lymph nodes from peptide immu-
nized mice. One out of four proliferation assay is shown for each
peptide.
doi:10.1371/journal.pone.0009863.g006
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amount of the immunizing peptide for 72 hours. Thymidine
(1 mCu) was added 18 hours before cell harvesting. Cells were
harvested on a Tomtec harvester (Model 94-3-468) and incorpo-
rated thymidine counted on a liquid scintillation counter (1450
Microbeta Wallac Trilux).
Supporting Information
Figure S1 Peptidomic profile of the human lymph. MS/MS
sequencing analysis of peptides found in the human lymph.
Found at: doi:10.1371/journal.pone.0009863.s001 (0.02 MB
DOC)
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